Significance StatementIn this phase I open‐label trial evaluating treatment of autism symptoms with autologous umbilical cord blood, changes in EEG spectral power were found by 12 months post‐treatment. Higher baseline posterior EEG beta power predicted greater improvement in symptoms.

Introduction {#sct312347-sec-0001}
============

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by social communication deficits and the presence of repetitive behaviors and restricted interests [1](#sct312347-bib-0001){ref-type="ref"}. Behavioral intervention, especially if provided early and intensively, can result in substantially improved outcomes [2](#sct312347-bib-0002){ref-type="ref"}. However, many individuals with autism exhibit significant impairments in social and communication abilities, despite having received early behavioral intervention. As such, there continues to be a great need for more effective treatments for ASD.

Evaluating the efficacy of novel treatments is challenging due to the heterogeneity of the disorder and lack of well‐validated brain‐based measures that can predict response to treatment and/or assess changes in neural functioning. Candidates for brain‐based ASD biomarkers include electroencephalography (EEG) [3](#sct312347-bib-0003){ref-type="ref"}, [4](#sct312347-bib-0004){ref-type="ref"}, [5](#sct312347-bib-0005){ref-type="ref"}, [6](#sct312347-bib-0006){ref-type="ref"}, fMRI [7](#sct312347-bib-0007){ref-type="ref"}, [8](#sct312347-bib-0008){ref-type="ref"}, [9](#sct312347-bib-0009){ref-type="ref"}, and MRI, including diffusion tensor imaging [10](#sct312347-bib-0010){ref-type="ref"}, [11](#sct312347-bib-0011){ref-type="ref"}, [12](#sct312347-bib-0012){ref-type="ref"}. EEG is of particular interest because it offers a feasible and relatively inexpensive way to assess changes in brain function with high temporal resolution, allowing for the characterization of aberrant brain networks with millisecond precision.

Several studies have demonstrated the potential usefulness of EEG as a biomarker related to treatment efficacy. Dawson et al. [13](#sct312347-bib-0013){ref-type="ref"} used EEG to measure treatment response to early intensive behavioral intervention based on the early start Denver model (ESDM) in a randomized controlled trial evaluating toddlers with ASD. Based on event related brain potentials (ERPs) to faces versus objects, it was found that the children who received ESDM behavioral intervention exhibited a faster neural response (shorter Nc ERP latency) when viewing faces than objects, whereas children receiving treatment as usual in the community showed the reverse pattern (shorter Nc latency to objects than to faces). Furthermore, children with ASD who had received ESDM showed a pattern of brain activity that was similar to a typically developing comparison group, characterized by increased cortical activation (reflected in decreased alpha power and increased theta power) while viewing faces compared with objects; the children receiving treatment as usual showed the reverse pattern. Normalized patterns of brain activity were correlated with improvements in social behavior. Faja et al. [14](#sct312347-bib-0014){ref-type="ref"} used face expertise training for individuals with ASD and found that the training was associated with improvement in recognition of inverted faces and timing of cortical responses recorded from ERPs. Additionally, Van Heck et al. [15](#sct312347-bib-0015){ref-type="ref"} used EEG markers of hemispheric symmetry to measure treatment response to the Program for the Education and Enrichment of Relational Skills in a randomized controlled trial for adolescents with ASD, finding that EEG symmetry was associated with more social contacts and knowledge and fewer ASD symptoms. These studies provide evidence that EEG is a promising efficacy biomarker in clinical trials for ASD.

Results from observational studies using EEG have helped to identify spatial and temporal abnormalities in children and adults with ASD as well as infants at risk for ASD. These studies offer potential treatment endpoints. Some of the key findings include disrupted cortical network connectivity [16](#sct312347-bib-0016){ref-type="ref"}, [17](#sct312347-bib-0017){ref-type="ref"}, [18](#sct312347-bib-0018){ref-type="ref"}, [19](#sct312347-bib-0019){ref-type="ref"}, an altered "resting state," [20](#sct312347-bib-0020){ref-type="ref"}, [21](#sct312347-bib-0021){ref-type="ref"} and atypical spectral power [16](#sct312347-bib-0016){ref-type="ref"}, [18](#sct312347-bib-0018){ref-type="ref"}, [22](#sct312347-bib-0022){ref-type="ref"}, [23](#sct312347-bib-0023){ref-type="ref"}, [24](#sct312347-bib-0024){ref-type="ref"}. In a recent review of EEG resting state studies, Wang et al. [21](#sct312347-bib-0021){ref-type="ref"} described a U‐shaped power profile of ASD characterized by excessive power in low‐frequency (delta, theta) and high‐frequency bands (gamma) and reduced power in a midrange frequency band (alpha, beta), which may result from abnormal GABAergic tone in inhibitory circuits. Furthermore, patterns of spectral power and functional connectivity have been found to be associated with severity of ASD symptoms and specific ASD subtypes [24](#sct312347-bib-0024){ref-type="ref"}, [25](#sct312347-bib-0025){ref-type="ref"}, [26](#sct312347-bib-0026){ref-type="ref"}, [27](#sct312347-bib-0027){ref-type="ref"}. Infants at high‐risk for ASD exhibit unique EEG profiles before the onset of the full syndrome, highlighting its potential use as an endophenotype before behavioral manifestations of ASD emerge [20](#sct312347-bib-0020){ref-type="ref"}, [24](#sct312347-bib-0024){ref-type="ref"}.

Although studies using EEG biomarkers in ASD clinical trials have primarily focused on alpha and theta activity, other frequency bands are relevant to ASD. Specifically, abnormalities in beta band activity (13--30 Hz), which has an established role in movement, movement preparation, and steady muscular contractions [28](#sct312347-bib-0028){ref-type="ref"}, [29](#sct312347-bib-0029){ref-type="ref"}, [30](#sct312347-bib-0030){ref-type="ref"}, [31](#sct312347-bib-0031){ref-type="ref"}, have been reported in ASD [16](#sct312347-bib-0016){ref-type="ref"}, [32](#sct312347-bib-0032){ref-type="ref"}, [33](#sct312347-bib-0033){ref-type="ref"}, [34](#sct312347-bib-0034){ref-type="ref"}, [35](#sct312347-bib-0035){ref-type="ref"}. Bangel et al. [36](#sct312347-bib-0036){ref-type="ref"} reported widespread reductions in beta phase synchrony in individuals with ASD during the presentation of globally coherent dot patterns, suggesting that disruptions in the beta band may contribute to the disrupted sensory and perceptual integration that is observed in ASD. Two studies have shown that beta band activity is disrupted during presentation of emotional faces in patients with ASD and typically developing individuals with high rates of ASD symptoms [37](#sct312347-bib-0037){ref-type="ref"}, [38](#sct312347-bib-0038){ref-type="ref"}. Another study found reduced long range beta connectivity in individuals with ASD during a visual name‐presentation task that included familiar names [39](#sct312347-bib-0039){ref-type="ref"}. Furthermore, reduced beta event related desynchronization during a motor imagery task was associated with ASD severity [33](#sct312347-bib-0033){ref-type="ref"}. Frohlich et al. [40](#sct312347-bib-0040){ref-type="ref"} investigated EEG biomarkers in the 15q11.2‐q13.1 gene (Dup 15q syndrome), a genetic copy number variant that accounts for 1%--3% of ASD cases. Increased beta power in Dup15q patients compared to typically developing children was found, further supporting the use of beta band activity to characterize ASD and related conditions. Taken together, these findings suggest that beta band activity shows substantial promise as a potential biomarker for ASD, in addition to the commonly studied theta and alpha bands.

This study is an analysis of secondary outcomes in an exploratory, open‐label, phase I clinical trial designed to test the safety of an intravenous infusion of autologous umbilical cord blood as a treatment for social communication impairments in ASD (*N* = 25). In addition to the primary purpose of assessing safety, this open‐label trial was designed to identify potential clinical outcomes and biomarkers that showed initial evidence of usefulness for a planned randomized, double‐blind clinical trial (*N* = 180), currently underway. The safety and primary clinical outcome data have previously been published [41](#sct312347-bib-0041){ref-type="ref"}. The purpose of this analysis was to explore whether EEG biomarkers show evidence of change after treatment and/or are useful in predicting response to treatment. Specifically, we explore whether (a) measures of EEG theta, alpha, and beta power change over a 12‐month period following treatment and (b) whether baseline EEG characteristics predict positive changes in social communication and language clinical outcomes.

Materials and Methods {#sct312347-sec-0002}
=====================

Study Design and Overview {#sct312347-sec-0003}
-------------------------

This study was a phase I, single‐center, and open‐label trial of a single intravenous infusion of autologous umbilical cord blood in 25 children with ASD. All children were initially enrolled in a screening protocol to obtain medical records and information about their banked cord blood unit. All participants\' caregivers completed a pre‐study screening interview by phone and provided medical records and videos for review by the study team to determine eligibility for the trial. Children with a confirmed diagnosis of ASD and a qualified banked autologous umbilical cord blood unit were eligible to participate. Written informed consent was obtained for both the screening and the treatment phases of the trial. The trial was approved by the Duke University Health System Institutional Review Board and conducted under IND \#15949. Participants and their caregivers traveled to Duke University three times as part of their participation in the study. At their baseline visit, they were evaluated and received a single intravenous autologous cord blood infusion. At 6 and 12 months post‐infusion, participants returned for follow‐up clinical assessments. Additional caregiver interviews and questionnaires were collected at 3 and 9 months post‐infusion.

Umbilical Cord Blood Units {#sct312347-sec-0004}
--------------------------

All participants had to have an available autologous umbilical cord blood unit banked at a family or public cord blood bank. During screening, potential participants\' cord blood reports were reviewed to ensure they met the following pre‐cryopreservation criteria: (a) total nucleated cell count (TNCC) of 1--5 × 10^7^ per kilogram, (b) sterility cultures which were performed and negative, (c) negative maternal infectious disease markers tested on the maternal donor or cord blood product (minimally including hepatitis B, hepatitis C, human immunodeficiency virus, human T‐lymphotrophic virus, and syphilis), and (d) test sample available for additional testing. If the participant and his/her cord blood unit were likely to be eligible, a sample of the cord blood unit was shipped to Duke for confirmation of identity and potency testing [42](#sct312347-bib-0042){ref-type="ref"}. Low‐resolution HLA testing was performed on both the participant and a sample of the cord blood unit for identity confirmation. If the CD45 viability on the test sample was \>40% and HLA‐identity was confirmed, the cryopreserved cord blood unit was shipped in a dry shipper to Duke Hospital Stem Cell Transplant Laboratory, where it was stored under liquid nitrogen until the day of infusion.

Autologous Umbilical Cord Blood Infusion {#sct312347-sec-0005}
----------------------------------------

On the day of infusion, the cord blood was thawed and washed in dextran 40 plus 5% human serum albumin (DA) and placed in 1.25 ml/kg DA for administration [43](#sct312347-bib-0043){ref-type="ref"}. Thawed cord blood units were tested for enumeration of TNCC, viable CD34 cells, colony‐forming units, cell viability via trypan blue, and sterility cultures. On the day of infusion, children were admitted to the Duke Children\'s Health Center Day Hospital, an outpatient treatment center, for their infusion. After premedication with Benadryl (0.5 mg/kg IV), Solu‐Medrol (0.5 mg/kg IV), and, if the child was awake and able to take oral medications, Tylenol (10 mg/kg PO), participants received either a portion of or their entire cord blood unit, adjusted to deliver 1--5 × 10^7^ cells per kilogram, via peripheral IV infusion more than 2--30 minutes. Intravenous fluids were administered at 1.5 times maintenance for 30 minutes to 2 hours after the cord blood infusion. Vital signs and pulse oximetry were monitored continuously during the infusion.

Participants {#sct312347-sec-0006}
------------

Participants between 2 and 6 years of age (median age 4.6 years; range 2.26--5.97) who met criteria for a clinical diagnosis of ASD based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) were included in the study. The DSM‐5 diagnosis of ASD was established by expert clinicians and informed by the Autism Diagnostic Observation Schedule, Second Edition [44](#sct312347-bib-0044){ref-type="ref"} and the Autism Diagnostic Interview, Revised [45](#sct312347-bib-0045){ref-type="ref"}. Additional inclusion criteria included (a) a nonverbal intelligence quotient (NVIQ) of ≥ 35 on the Stanford--Binet Intelligence Scales for Early Childhood, Fifth Edition [46](#sct312347-bib-0046){ref-type="ref"} or Mullen Scales of Early Learning [47](#sct312347-bib-0047){ref-type="ref"}, (b) availability of a qualified autologous umbilical cord blood unit, (c) participant was stable on their current medications for at least 2 months prior to the infusion, (d) ability to travel to Duke University three times (baseline and 6 and 12 months post‐baseline), and (e) parents were English speaking. Exclusion criteria included (a) a history of prior cell therapy, (b) use of intravenous immunoglobulin or other anti‐inflammatory medications (with the exception of non‐steroidal anti‐inflammatory drugs), (c) known genetic (e.g., fragile X) or other significant medical comorbidity, (d) obvious physical dysmorphology suggestive of a genetic syndrome, (e) an uncontrolled seizure disorder, (f) significantly impaired renal or liver function, and (g) clinically significant abnormalities in complete blood count. See Table [1](#sct312347-tbl-0001){ref-type="table"} for baseline characteristics of the sample.

###### 

Baseline characteristics of included participants

  Characteristics                                    Value (*n* = 25)
  ------------------------------------------------- -------------------
  Sex, no. (%)                                      
  Male                                                  21 (84.0%)
  Female                                                 4 (16.0%)
  Age, yr, median (range)                            4.62 (2.26--5.97)
  Race, no. (%)                                     
  White                                                  22 (88%)
  Other                                                   3 (12%)
  Ethnicity, no. (%)                                
  Hispanic                                                2 (8%)
  Non‐Hispanic                                           23 (92%)
  ADOS severity score, median (range)                    8 (6--10)
  Nonverbal intelligence quotient, median (range)      65 (22--123)
  CGI‐S, no. (%)                                    
  Barely evident                                         4 (16.0%)
  Moderate ASD symptoms                                  3 (12.0%)
  Moderately severe ASD                                 10 (40.0%)
  Severe ASD symptoms                                    8 (32.0%)

Abbreviations: ADOS, Autism Diagnostic Observation Schedule; ASD, autism spectrum disorder; CGI‐S, Clinical Global Impression‐Severity.

Clinical outcome measures {#sct312347-sec-0007}
-------------------------

### Social Communication Skills {#sct312347-sec-0008}

The primary endpoint was the Vineland adaptive behavior scales‐II (VABS) [48](#sct312347-bib-0048){ref-type="ref"} socialization subscale standard score. VABS is a well‐standardized measure with strong reliability and validity. The VABS was collected from the participant\'s primary caregiver at baseline and 6‐ and 12‐month visits.

### Expressive Language {#sct312347-sec-0009}

The expressive one word picture vocabulary test 4 (EOWPVT) [49](#sct312347-bib-0049){ref-type="ref"} is a clinician‐administered assessment which measures an individual\'s ability to match a spoken word with an image of an object, action, or concept. The EOWPVT was administered to each child at the baseline and 6‐ and 12‐month visits. The change in the raw score, a count of the number of spoken words, was used to measure change in expressive language over the course of the trial.

### Clinical Improvement {#sct312347-sec-0010}

The clinical global impression‐improvement (CGI‐I) scale is a commonly used rating scale that measures clinical improvement as baseline [50](#sct312347-bib-0050){ref-type="ref"}. The CGI‐I is a seven‐point scale indicating the degree of improvement or worsening of ASD symptoms relative to baseline. Based on all available information, each participant was rated as 1 = "very much improved"; 2 = "much improved"; 3 = "minimally improved"; 4 = "no change"; 5 = "minimally worse"; 6 = "much worse"; or 7 = "very much worse." Each participant was assigned a CGI‐I rating at the 6‐ and 12‐month visits, and each referenced the degree of improvement or worsening relative to baseline. Ratings were made by experienced clinicians with expertise in ASD.

EEG Measures {#sct312347-sec-0011}
------------

### Protocol {#sct312347-sec-0012}

Electroencephalography data were collected at baseline, 6‐ and 12‐month visits. Continuous EEG was recorded while three videos were shown twice to participants (total of 6 videos, 6 minutes). Video content included nursery rhymes (high social content, video 1), brightly colored toys (low social content, video 2), and bubbles (low social content, video 3). The order of videos was counterbalanced to eliminate any potential order effects. During the stimulus presentation, two behavioral assistants accompanied the child. The behavioral assistants ensured that standard conditions were in place during each experiment, including dimming the lights, seating participants in their parent\'s lap in a comfortable armchair 65 inches from the monitor and redirecting participants in instances of movement and/or poor attention to the videos. Video recording synchronized with the EEG was used throughout the session to allow post‐session editing of periods of inattention. EEG data were recorded from 124 electrodes with reference to Cz using a Hydrocel Geodesic Sensor Net and Net Amps 400 amplifier (Electrical Geodesics, Eugene, OR). Data were collected using Netstation 4.5.6 with a sampling rate of 1,000 Hz.

### EEG Preprocessing and Data Attrition {#sct312347-sec-0013}

Data were processed using in‐house code and the open source Fieldtrip tool box [51](#sct312347-bib-0051){ref-type="ref"} under MATLAB 2014a. Data were filtered with a 1--100 Hz bandpass filter and a 60 Hz notch filter. Participant videos were inspected for inattention to the video and gross movement artifact, and these time points were removed from analyses. Persistent bad electrodes that were deviant in 33% of trials were interpolated using spline interpolation. Data were decomposed using second order blind identification (SOBI) as implemented in EEGLAB [52](#sct312347-bib-0052){ref-type="ref"}, [53](#sct312347-bib-0053){ref-type="ref"}. Topographic maps of SOBI components were inspected and electrooculogram and electromyogram components were removed. The best 30--40 one second epochs with minimal movement contamination were retained. Remaining deviant electrodes were identified on a trial‐by‐trial basis and interpolated. Data were then re‐referenced to the common average. Finally, a fast Fourier transformation was performed on the rectangular windowed time series. For each of the three stimulus conditions, the presentation with the least amount of movement artifact was used for the final analysis.

Of the 25 total participants in the trial, 18 participants (72% of original sample) were able to provide sufficient artifact‐free data during the baseline visit in all three stimulus conditions (toys, social, and bubbles) and were included in this analysis. At the 6‐month visit 17 participants (94% of baseline sample, 68% of original sample) provided data for the toys and social conditions while 16 participants (89% of baseline sample, 64% of original sample) provided data for the bubbles condition. At the 12‐month visit 18 participants (100% of baseline sample, 72% of original sample) provided data for all three stimulus conditions. Attrition was due to drop out, noncompliance with study procedures, and excessive movement artifact.

### EEG Variables {#sct312347-sec-0014}

Absolute and relative spectral power (defined between 3 and 30 Hz) was examined during the social, toys, and bubbles conditions in three brain regions of interest (frontal, central, and posterior), per McEvoy et al. [54](#sct312347-bib-0054){ref-type="ref"} Twelve electrodes covering the left hemisphere, right hemisphere, and midline were included in each of the three regions. Power values for each region were calculated by averaging the 12 electrodes within the region. The four power bands analyzed consisted of theta power (5--7 Hz), alpha power (8--10 Hz), beta 1 power (11--20 Hz), and beta 2 power (21--30 Hz).

Statistical Analysis {#sct312347-sec-0015}
--------------------

To evaluate whether there were significant changes in EEG power over time, the 6‐ and 12‐month time points were compared to the baseline time point using repeated‐measures ANOVA. Next, to evaluate whether baseline EEG measures were predictive of clinical outcomes, bivariate linear regression models were conducted. For baseline EEG measures that were found to be predictive of clinical outcome, we also evaluated whether baseline EEG improved prediction of outcomes beyond prediction based on models using only NVIQ, which was previously found to be a strong predictor in our primary analyses of clinical outcomes [41](#sct312347-bib-0041){ref-type="ref"}.

All EEG data were log‐transformed to correct for skewness. The log‐transformed data followed a normal or near normal distribution and the data met the assumptions for linear regression including no outliers and independent observations. Baseline NVIQ scores were standardized by subtracting the grand mean from each score and dividing this difference by the standard deviation of the sample. A *p* value of .05 was chosen to establish statistical significance. Statistical analyses were performed using SAS software Version 9.4 (SAS Institute, Inc., Cary, NC).

Results {#sct312347-sec-0016}
=======

EEG Changes Over Time {#sct312347-sec-0017}
---------------------

### Absolute EEG Power {#sct312347-sec-0018}

Mean and standard deviations for baseline EEG absolute power variables are shown in Table [2](#sct312347-tbl-0002){ref-type="table"}. A significant reduction in absolute posterior theta power during the bubbles condition was found at 12 months (*F*(1, 32) = 4.81, *p* = .04). Significant increases in absolute frontal alpha power during the social and bubbles conditions were found at 6 months (*F*(1, 33) = 4.13, *p* = .05 and *F*(1, 32) = 4.41, *p* = .04, respectively). No significant changes in absolute beta power were found.

###### 

Mean and standard deviations for baseline EEG absolute power variables (μV^2^)

                Toys EEG power   Social EEG power   Bubbles EEG power                           
  ------------- ---------------- ------------------ ------------------- ----------- ----------- -----------
  Theta                                                                                         
  (5--7 Hz)     Frontal          6.0 (2.8)          Frontal             5.6 (2.2)   Frontal     5.7 (2.4)
                Central          5.8 (3.5)          Central             5.7 (3.1)   Central     6.1 (3.5)
                Posterior        6.9 (3.8)          Posterior           7.4 (3.9)   Posterior   8.7 (5.6)
  Alpha                                                                                         
  (8--10 Hz)    Frontal          3.2 (1.5)          Frontal             2.9 (1.4)   Frontal     2.9 (1.3)
                Central          4.4 (2.8)          Central             4.2 (2.8)   Central     3.8 (2.3)
                Posterior        4.6 (2.1)          Posterior           4.1 (2.1)   Posterior   4.8 (2.3)
  Beta 1                                                                                        
  (11--20 Hz)   Frontal          1.0 (0.7)          Frontal             1.0 (0.9)   Frontal     0.9 (0.5)
                Central          0.7 (0.4)          Central             0.7 (0.4)   Central     0.6 (0.3)
                Posterior        0.8 (0.3)          Posterior           0.7 (0.3)   Posterior   0.8 (0.3)
  Beta 2                                                                                        
  (21--30 Hz)   Frontal          0.9 (1.4)          Frontal             0.8 (1.1)   Frontal     0.7 (0.8)
                Central          0.4 (0.4)          Central             0.4 (0.3)   Central     0.3 (0.2)
                Posterior        0.3 (0.2)          Posterior           0.3 (0.2)   Posterior   0.3 (0.2)

Abbreviation: EEG, electroencephalography.

### Relative EEG Power {#sct312347-sec-0019}

A significant reduction in relative posterior theta power during the social condition was found at 12 months (*F*(1, 33) = 4.98, *p* = .03). A significant increase in relative central alpha power was observed during the toys condition at 6 months (*F*(1, 33) = 4.21, *p* = .05). A significant increase in relative frontal and central alpha power was found during the toys condition at 12 months (*F*(1, 33) = 5.20, *p* = .029 and *F*(1, 33) = 3.94, *p* = .055, respectively). Significant or marginally significant increases in relative posterior beta 1 power (11--20 Hz) were found during the bubbles, toys, and social conditions at 12 months (*F*(1, 32) = 4.19, *p* = .048; *F*(1, 33) = 3.63, *p* = .065; *F*(1, 33) = 3.88, *p* = .057, respectively).

EEG Prediction of Clinical Outcomes {#sct312347-sec-0020}
-----------------------------------

Baseline relative EEG alpha, theta, and beta power and baseline absolute alpha and theta baseline power measures recorded over the frontal, central, and posterior regions were not found to be predictive of clinical outcomes (all *p*s \> .05). However, consistent correlations between baseline absolute beta EEG power and the VABS socialization subscale score (the primary endpoint) were found. Correlations between the primary endpoint (Vineland social communication standard score) and baseline beta 2 absolute power are shown in Table [3](#sct312347-tbl-0003){ref-type="table"}. These significant associations were driven primarily by baseline absolute posterior beta 2 power (21--30 Hz) as can be seen in Table [3](#sct312347-tbl-0003){ref-type="table"}. Specifically, higher posterior beta 2 power was associated with increases in social abilities on the VABS across all three video conditions. Correlations between posterior beta 2 power and the EOWPVT and CGI‐I outcomes were only marginally significant or nonsignificant.

###### 

Correlations between primary endpoint (Vineland social communication) and baseline beta 2 absolute power with unadjusted *p* values

  Brain region   Condition   *p* value
  -------------- ----------- --------------------------------------------------
  Frontal        Bubbles     N.S.
                 Toys        N.S.
                 Social      N.S.
  Central        Bubbles     .42[†](#sct312347-note-0003){ref-type="fn"}
                 Toys        N.S.
                 Social      N.S.
  Posterior      Bubbles     .41[†](#sct312347-note-0003){ref-type="fn"}
                 Toys        .77[\*\*\*](#sct312347-note-0003){ref-type="fn"}
                 Social      .56[\*](#sct312347-note-0003){ref-type="fn"}

^†^ *p* \< .10, \**p* \< .05, \*\**p* \< .01, \*\*\**p* \< .001.

Abbreviation: N.S., nonsignificant.

In light of the finding that posterior beta 2 power was significantly correlated with our primary endpoint across both the toys and social conditions, we next examined whether posterior beta 2 power, recorded in these two conditions, improved our ability to predict clinical outcomes at the 12‐month visit beyond prediction based on nonverbal NVIQ at the 12‐month visit. Baseline NVIQ was found to be strongly correlated with clinical outcomes, as reported in our previous paper. In this subsample of children who had EEG data for this study, baseline NVIQ was again found to be associated with improvement on the VABS socialization subscale (*R* ^2^ = .21, *p* = .06) at 12 months follow‐up. Children with higher baseline NVIQ were predicted to show more improvement in the clinical outcome, with NVIQ explaining 21% of the variance in the social communication outcome. However, adding EEG in a regression model using Type I SS (i.e., where each parameter is adjusted only for the preceding effects in the model) demonstrated that beta 2 power significantly improved model predictions. NVIQ and baseline posterior absolute beta 2 power from the toys condition together explain 64% of the variance in VABS socialization subscale score (*R* ^2^ = .64, *p* \< .001) at 12 months. NVIQ and baseline posterior absolute beta 2 power from the social condition together explain 44% of the variance in the social communication outcome (*R* ^2^ = .44, *p* = .02). Figures [1](#sct312347-fig-0001){ref-type="fig"} and [2](#sct312347-fig-0002){ref-type="fig"} show regression plots with prediction and confidence limits. The blue lines and blue shading are regression plots that included baseline NVIQ. The red lines and red shading are the final regression plot that included the addition of beta 2 power (order‐dependent or hierarchical) and illustrate the improvement in prediction achieved by including this information.

![Hierarchical regression plots, including CLM and CLI, predicting VABS socialization subscale from baseline NVIQ and EEG beta 2 absolute power in the toys condition. Abbreviations: CLI, confidence limit interval; CLM, confidence limit for the mean; EEG, electroencephalography; NVIQ, nonverbal intelligence quotient; VABS, Vineland adaptive behavior scales‐II.](SCT3-7-783-g001){#sct312347-fig-0001}

![Hierarchical regression plots, including CLM and CLI, predicting VABS socialization subscale from baseline NVIQ and EEG beta 2 absolute power in the social condition. Abbreviations: CLI, confidence limit interval; CLM, confidence limit for the mean; EEG, electroencephalography; NVIQ, nonverbal intelligence quotient; VABS, Vineland adaptive behavior scales‐II.](SCT3-7-783-g002){#sct312347-fig-0002}

Discussion {#sct312347-sec-0021}
==========

In this phase I open‐label study, we explored whether EEG biomarkers show evidence of change after intravenous treatment with autologous umbilical cord blood in young children with autism. In addition, we tested whether measures derived from spontaneous EEG were useful in predicting degree of improvement in social communication abilities. In this sample of 25 children who were found to exhibit improvements in social communication (VABS), expressive language (EOWPVT), and overall clinical improvement, as assessed via the CGI‐I [41](#sct312347-bib-0041){ref-type="ref"}, we first explored whether there was any evidence of change in the spectral characteristics of the EEG, as assessed via recordings of spontaneous EEG taken while children watched movies with differing content at baseline, and 6 and 12 months post‐treatment. Of particular interest is the U‐shaped power profile of ASD characterized by excessive power in low‐frequency (delta, theta) and high‐frequency bands (gamma) and reduced power in midrange frequency bands (alpha, beta) [21](#sct312347-bib-0021){ref-type="ref"}. Interestingly, the children in this study showed a "normalization" of spectral features of their EEG, characterized by significant reductions in both absolute and relative theta power over the posterior regions and significant increases in absolute frontal alpha power and in relative frontal and central alpha power, as well as increases in relative posterior beta power (11--20 Hz) by 12 months post‐treatment. Evidence of increases in relative posterior beta power at 12 months were also found. Evidence suggests that autism is associated with disruptions in GABAergic interneuron development [55](#sct312347-bib-0055){ref-type="ref"}, [56](#sct312347-bib-0056){ref-type="ref"}, [57](#sct312347-bib-0057){ref-type="ref"} which may be caused by an excitatory/inhibitory imbalance [58](#sct312347-bib-0058){ref-type="ref"}. Such disruptions have been posited as an explanation for reduction in alpha frequencies often found in autism, as this would reflect higher than normal levels of excitation [21](#sct312347-bib-0021){ref-type="ref"}. Increased power in lower frequencies, such as theta and delta, might reflect compensatory mechanisms. In this study, this atypical pattern shifted toward a more normal pattern (increased alpha and decreased theta power).

Changes in EEG spectral characteristics were more frequently observed 12 months post‐infusion than 6 months post‐infusion, possibly because EEG changes are related to more long‐term restructuring of neural circuitry. Distinct changes were observed for videos with high social content and low social content. The different stimulus conditions may represent conditions of varying reward value which dictate engagement states. The differential results by stimulus type suggest that the EEG changes over time are caused by differential changes in reward value. This aligns with Stavropoulos and Carver [59](#sct312347-bib-0059){ref-type="ref"} who report reward related changes in alpha and theta bands. The authors hypothesized that the abnormalities in reward evaluation and processing common in ASD are associated with differences in theta (reward processing) and alpha (engagement state) bands. More work will be needed to determine if umbilical cord blood therapy may be influencing reward processing and engagement states, and thus positively impacting social communication abilities and peer relations, in young children with ASD.

Based on an increasing number of studies demonstrating beta band disruptions in individuals with ASD compared to TD controls [33](#sct312347-bib-0033){ref-type="ref"}, [36](#sct312347-bib-0036){ref-type="ref"}, [37](#sct312347-bib-0037){ref-type="ref"}, [38](#sct312347-bib-0038){ref-type="ref"}, [39](#sct312347-bib-0039){ref-type="ref"} we hypothesized that indices of beta band power may be sensitive to change over the course of the clinical trial. Not only were changes in relative beta power statistically significant at 12 months post‐infusion in posterior brain regions (toys, social, and bubbles conditions), but baseline beta power was also predictive of improved social communication skills, as measured via parent report on the VABS. Higher baseline beta power was associated with more improvement in the social communication clinical outcome. Baseline NVIQ alone explained 21% of the variance in the social communication outcome, while baseline NVIQ and beta power during the toys condition together explained 64% of the variance in the outcome. This indicates that a large percentage of variance can be explained using only two explanatory variables, which is advantageous because there is a reduced chance of overfitting and explaining random noise that is unique to the current sample. These exploratory findings will allow predictions in our larger placebo‐controlled trial evaluating the efficacy of umbilical cord blood in young children with ASD, which is underway.

The present results are encouraging as they suggest that beta band spectral power may be used to identify patients that will respond well to the umbilical cord blood treatment. Only baseline posterior beta power, and not theta or alpha power, was associated with clinical improvement. Furthermore, posterior beta power increased significantly in the trial. Beta oscillations have been theorized to serve larger scale communication between sensorimotor regions and distant brain regions [29](#sct312347-bib-0029){ref-type="ref"} allowing for the "maintenance of the current sensorimotor or cognitive state" [60](#sct312347-bib-0060){ref-type="ref"}. Deficits in executive functioning, including response inhibition, cognitive flexibility, working memory, and adaptability, are well‐established in individuals with ASD [61](#sct312347-bib-0061){ref-type="ref"}, [62](#sct312347-bib-0062){ref-type="ref"}, [63](#sct312347-bib-0063){ref-type="ref"}, [64](#sct312347-bib-0064){ref-type="ref"}. Beta oscillations may play a role in cognitive flexibility and maintaining a status quo despite changes in the external environment. As individuals with more severe ASD symptoms have demonstrated reduced beta power [33](#sct312347-bib-0033){ref-type="ref"}, beta band disruptions may be contributing to executive function deficits. In this study, participants with higher beta power at the onset of the trial demonstrated more improvement than those with lower beta power. Children with ASD with higher beta power may have more skills related to integrating information and adapting to change, thus allowing for greater improvement in complex domains such as socialization and communication.

The current findings may be influenced by follow‐up duration, treatment expectancy, and participant age. New patterns of EEG power may manifest after 12 months; likewise, changes we did observe may no longer be present after the 12‐month follow‐up time. Future work should incorporate more longitudinal time points to model the developmental trajectory of EEG power. While changes in EEG power will not be affected by parental expectancy (i.e., placebo effect), the associations between EEG power and parent‐reported clinical outcomes may be sensitive to differences in treatment expectancy. Future double‐blind placebo‐controlled trials will help to control for this bias. Finally, we expect differential brain growth over the course of 1 year in the youngest and oldest children due to differences in developmental stages across the 2--6 years age range. In an open‐label trial, we cannot attribute the positive changes in EEG observed to the umbilical cord treatment. However, we provide preliminary evidence that measures of EEG power in theta, alpha, and beta bands are sensitive to change over the course of a 12‐month open‐label clinical trial testing umbilical cord blood therapy for ASD, and that an EEG biomarker shows promise in identifying children who are likely to exhibit the highest level of improvement in their social communication skills.

Conclusion {#sct312347-sec-0022}
==========

We demonstrated the feasibility of using EEG measures in an open‐label, phase I trial of intravenous infusion of autologous umbilical cord blood in young children with ASD. We described significant changes in EEG power reflected in a normalization of the EEG spectral characteristics by 12 months post‐infusion. Furthermore, higher baseline EEG beta 2 power was associated with a greater degree of improvement in social communication symptoms. Baseline measures of EEG beta 2 power and NVIQ together were highly predictive of treatment response, highlighting the potential for EEG as a tool to discriminate between children with varying degrees of improvement after treatment with autologous umbilical cord blood. These outcomes will be further evaluated on completion of the ongoing randomized phase II, placebo‐controlled study of cord blood in young children with ASD.
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